Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Reticulocytes, haemolysis and bone-marrow response

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Rapid haemoglobin fall with shock, chest pain, hypoxia, haemoglobinuria, severe hyperkalaemia, transfusion-reaction symptoms, microangiopathic haemolysis with thrombocytopenia, or haemolysis during pregnancy requires immediate stabilisation and specialist assessment. Take diagnostic samples promptly, but do not delay treatment of circulatory or organ compromise.

Purpose and principles

Use the absolute reticulocyte response and a coherent haemolysis profile to distinguish red-cell underproduction, loss and destruction, then select immune, membrane, enzyme or mechanical testing.

Reticulocytes are newly released red cells containing residual RNA. Their absolute number is a practical measure of marrow erythroid output. In anaemia, an appropriate response indicates that marrow can increase production and directs attention towards recent blood loss or peripheral destruction. A low or inappropriately normal response suggests impaired substrate, erythropoietin, progenitor or marrow function. The response is dynamic: it may be absent very early after bleeding, rise during recovery from deficiency, and be blunted when destructive and production problems coexist.

Haemolysis is a mechanism, not a final diagnosis. Red-cell destruction raises unconjugated bilirubin and LDH, consumes haptoglobin and stimulates reticulocytosis. Intravascular destruction may add haemoglobinaemia, haemoglobinuria and haemosiderinuria; extravascular destruction in macrophages often causes splenomegaly and jaundice. None of these markers is perfectly specific. LDH can rise from tissue injury or ineffective erythropoiesis, haptoglobin rises as an acute-phase reactant and falls in liver disease, and bilirubin depends on hepatic handling.

Indications, selection and cautions

Regenerative anaemia

A raised absolute reticulocyte count with polychromasia indicates increased marrow output, most often after blood loss, haemolysis or effective treatment of a prior deficiency.

Hypoproliferative anaemia

A low response despite anaemia points toward iron, B12 or folate deficiency, renal disease, inflammation, infection, aplasia, infiltration or medicine-related marrow suppression.

Intravascular haemolysisRed flag

Back or abdominal pain, dark urine, haemoglobinaemia, marked haptoglobin depletion and acute kidney or potassium disturbance suggest red-cell destruction within the circulation.

Extravascular haemolysis

Jaundice, splenomegaly, spherocytes and a more chronic course support macrophage-mediated destruction in spleen or liver, including warm immune and membrane disorders.

Microangiopathic emergencyRed flag

Anaemia, thrombocytopenia, schistocytes, high LDH and organ ischaemia raises TTP, HUS, DIC or severe hypertension and requires immediate mechanism-directed assessment.

Method and interpretation

  1. 01
    Absolute reticulocyte countFirst step
    Why
    Measure effective marrow erythroid output in relation to the anaemia.
    Interpretation and limitations
    A high absolute count supports regeneration, but interpret the interval from bleeding or treatment and whether the rise is sufficient. A percentage without correction can mislead in severe anaemia.
  2. 02
    Bilirubin, LDH and haptoglobin
    Why
    Demonstrate biochemical red-cell destruction and estimate its activity.
    Interpretation and limitations
    Concordant indirect hyperbilirubinaemia, raised LDH and low haptoglobin strengthens haemolysis. Discordance prompts review of liver function, inflammation, ineffective erythropoiesis, tissue injury and sampling.
  3. 03
    Peripheral blood film
    Why
    Identify morphology that localises the destructive mechanism or reveals marrow response.
    Interpretation and limitations
    Polychromasia reflects reticulocytes; spherocytes, schistocytes, bite cells, agglutination, parasites or abnormal marrow cells each direct a different confirmatory pathway.
  4. 04
    Direct antiglobulin test
    Why
    Detect immunoglobulin or complement coating and support immune haemolysis classification.
    Interpretation and limitations
    Interpret IgG and complement patterns with recent transfusion, pregnancy, medicines and cold-reactive symptoms. A negative test does not completely exclude immune haemolysis when the phenotype is compelling.

Clinical next steps

01ConfirmProve haemolysis and grade urgencyFirst stepHaemoglobin is falling or jaundice, dark urine, splenomegaly or a regenerative count suggests red-cell destruction.+
  1. 1First lineFirst-line testing is FBC, absolute reticulocytes, film, bilirubin fractions, LDH, haptoglobin, DAT, renal profile and urinalysis, alongside observations and a bleeding assessment.
  2. 2AlternativeCheck prior counts, transfusion and medicine timing, liver disease, infection, pregnancy and prosthetic valves; an alternative diagnosis is blood loss when reticulocytosis occurs without a convincing destructive profile.
  3. 3EscalationEscalate shock, symptomatic rapid anaemia, hyperkalaemia, renal injury, transfusion reaction or thrombocytopenic fragmentation for immediate specialist and transfusion support.
02Classify

Risks, monitoring and follow-up

  • During active haemolysis trend haemoglobin, reticulocytes, bilirubin, LDH, haptoglobin, creatinine, potassium and symptoms at a frequency matched to the rate of change.
  • Record transfusion timing and expected post-transfusion change; an inadequate increment or renewed fall can signal continuing haemolysis, bleeding or sampling dilution.
  • Monitor cause-specific endpoints, such as haemoglobin and biochemical destruction in AIHA, platelet and LDH response in TMA, or recovery after stopping an oxidant trigger; DAT strength alone is not a reliable activity marker.
  • After treatment of an underproduction cause, look for an appropriate reticulocyte rise before expecting full haemoglobin normalisation.
  • Reassess the diagnosis when markers disagree, reticulocytes fail to rise, or marrow response remains poor despite correction of nutrients and renal or inflammatory contributors.

Special situations

Reticulocyte percentage can flatter

When mature red cells are depleted, reticulocytes form a larger percentage without a large absolute output. The absolute count prevents this denominator error.

Haemolysis can be mixed

A patient can have immune destruction plus iron deficiency, renal impairment or marrow infiltration. The reticulocyte response may therefore be less impressive than expected.

Haptoglobin has two masters

It falls by binding free haemoglobin but rises during inflammation. A normal result in an inflamed patient does not completely dismiss haemolysis.

Ineffective erythropoiesis mimics destruction

Severe megaloblastic deficiency can raise LDH and indirect bilirubin as precursors die within marrow, yet the circulating reticulocyte response remains inadequate.

Timing protects enzyme diagnosis

Older deficient cells are destroyed first in a G6PD crisis, leaving reticulocytes with higher activity. Testing during recovery may require later confirmation.

Common pitfalls

  1. 01

    Using a reticulocyte percentage without checking the absolute count and severity of anaemia.

  2. 02

    Diagnosing haemolysis from isolated raised LDH without bilirubin, haptoglobin, reticulocytes and film.

  3. 03

    Assuming a positive DAT always means clinically active haemolysis.

  4. 04

    Missing blood loss because reticulocytosis is labelled haemolysis automatically.

  5. 05

    Ruling out G6PD deficiency from a result taken during brisk reticulocytosis.

  6. 06

    Ignoring recent transfusion when interpreting morphology, DAT and inherited red-cell tests.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Reticulocytes in profound anaemia

A patient has haemoglobin 68 g/L. Reticulocytes are reported as 3%, but the absolute reticulocyte count is not raised. Bilirubin and haptoglobin are normal. What is the best interpretation?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSH autoimmune haemolytic anaemia guidelineHaemolysis confirmation, DAT interpretation and immune classification.
  • BSH thrombotic microangiopathy guidelineFragmentation, ADAMTS13 sampling and urgent TTP pathway.
  • NICE NG239 vitamin B12 recommendationsRecognition of ineffective erythropoiesis and treatment response in B12 deficiency.
  • BNF anaemias treatment summaryUK approach to anaemia, haematinic therapy and response monitoring.
  • BNF G6PD deficiency guidanceCurrent UK oxidant-medicine risk and prescribing safety in G6PD deficiency.
  • NHS Genomics Education G6PD deficiencyInheritance, oxidant-triggered haemolysis and limitations of enzyme activity testing during an acute episode.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

After confirming haemolysis, separate immune from non-immune causes and congenital from acquired disease. The DAT, film and history provide the first branch. Spherocytes with a positive DAT support warm immune haemolysis; agglutination and complement coating suggest a cold process; bite cells after an oxidant trigger suggest G6PD deficiency; schistocytes suggest fragmentation; parasites or an unstable haemoglobin require their own tests. Always ask about valves, pregnancy, transfusion, infections, autoimmune disease, lymphoid cancer and new medicines because the cause determines urgency and recurrence prevention.

Key points

  • Use the absolute reticulocyte count, not the percentage alone. A percentage can appear high simply because the circulating red-cell denominator is low.
  • Ask whether the response is appropriate for the depth and duration of anaemia. Reticulocytes take time to rise, and severe iron, B12 or folate deficiency can limit a response despite haemolysis.
  • A typical haemolysis pattern combines raised indirect bilirubin and LDH, low haptoglobin, reticulocytosis and film change, but inflammation, liver disease, ineffective erythropoiesis and recent transfusion can alter individual markers.
  • Intravascular haemolysis releases free haemoglobin into plasma and urine and may lower haptoglobin markedly; extravascular haemolysis occurs mainly in spleen and liver and often produces spherocytes and splenomegaly.
  • The direct antiglobulin test identifies immunoglobulin or complement on red cells. It supports immune coating but must be interpreted after recent transfusion, medicines and laboratory specificity.
  • Schistocytes with thrombocytopenia suggest a thrombotic microangiopathy or DIC pathway; preserved coagulation supports TTP but does not replace ADAMTS13 and urgent specialist assessment.
  • A low reticulocyte response directs attention to marrow suppression, renal erythropoietin deficiency, nutrient lack, infection, inflammation or infiltration rather than assuming occult bleeding.
  • Recent red-cell transfusion mixes donor and patient cells, modifies indices and haemolysis tests, and can create alloimmune reactions; record unit timing before interpreting the panel.
  • 05
    Urine haemoglobin and renal profile
    Why
    Identify intravascular haemolysis and organ consequences.
    Interpretation and limitations
    Dipstick blood with few red cells supports free haemoglobin or myoglobin; plasma appearance, creatinine, potassium and clinical context distinguish mechanisms and determine monitoring urgency.
  • 06
    Cause-directed enzyme, membrane, haemoglobin and marrow tests
    Why
    Confirm the underlying disorder after the first haemolysis branch.
    Interpretation and limitations
    Use G6PD testing, eosin-5-maleimide binding, haemoglobin analysis, cold-antibody studies, flow cytometry or marrow assessment after specialist and laboratory discussion; timing after crisis or transfusion affects validity.
    • Separate immune from non-immune destruction
    The haemolysis profile is supported and the patient is physiologically stable enough for cause-directed testing.
    +
    1. 1PreferredUse DAT pattern, film and clinical context as the preferred branch: IgG-associated spherocytosis suggests warm AIHA, complement and agglutination suggests cold disease, and fragments suggest mechanical injury.
    2. 2AlternativeWhen DAT is negative, assess oxidant triggers, family and ethnic history, haemoglobinopathy, membrane disease, parasites, valves and microangiopathy; specialist enhanced DAT testing is an alternative when immune disease remains likely.
    3. 3DefinitiveChoose definitive tests at the correct time, repeating G6PD after recovery if the acute result may be falsely normal and postponing inherited red-cell testing after transfusion when donor cells confound it.
    03Low outputInvestigate an inadequate marrow responseAnaemia is present but the absolute reticulocyte count is low or inappropriately normal.+
    1. 1Assess ferritin and transferrin saturation, B12, folate, renal, thyroid, liver and inflammatory status and review marrow-toxic medicines, alcohol and recent viral illness.
    2. 2PreferredThe preferred next test follows the phenotype: replace a confirmed deficiency and monitor response, investigate renal or inflammatory disease, or use viral and autoimmune testing when clinically directed.
    3. 3EscalationEscalate persistent unexplained reticulocytopenia, pancytopenia, abnormal film or constitutional symptoms to haematology for flow, molecular or bone-marrow assessment.
    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom